Clinical Trials Logo

Peanut Allergy clinical trials

View clinical trials related to Peanut Allergy.

Filter by:

NCT ID: NCT06331728 Not yet recruiting - Peanut Allergy Clinical Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents.

NCT ID: NCT06297083 Recruiting - Peanut Allergy Clinical Trials

Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy

HILO
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This study will compare the effectiveness of three different treatments to treat peanut allergy

NCT ID: NCT06256146 Recruiting - Peanut Allergy Clinical Trials

Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

IMPROVES
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Protocols for Oral Immunotherapy (OIT) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in European and Canadian official guidelines. There has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. This study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.

NCT ID: NCT05695261 Recruiting - Food Allergy Clinical Trials

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Start date: June 8, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.

NCT ID: NCT05667610 Recruiting - Peanut Allergy Clinical Trials

Immune-supportive Diet and Gut Permeability in Allergic Children

DIAMETER
Start date: September 8, 2022
Phase: N/A
Study type: Interventional

Peanut and nut allergy can be life threatening. Some patients have very low threshold levels (i.e. the amounts of peanut and nuts to which the patients react), others react to higher doses. The reasons for these differences in threshold are not well understood. Patients with peanut and nut allergy often suffer from other allergic diseases (atopic dermatitis, hay fever and asthma). A disturbed gut microbiota composition and an increased gut permeability may explain the development of allergic disease. We hypothesize that increased gut permeability is related to low threshold levels to peanuts or nuts. In addition, as it is known that nutrition can influence our gut permeability, we also hypothesize that a healthful immune-supportive diet restores gut permeability and alleviates symptoms. Therefore, the purpose of the study is to study in peanut and nut allergic children: 1. the relationship between gut permeability and threshold levels to peanut or nuts; 2. the effect of an immune-supportive diet on gut permeability, gut microbiome composition, coexisting allergic symptoms and quality of life

NCT ID: NCT05662800 Recruiting - Atopic Dermatitis Clinical Trials

Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy

Start date: April 17, 2023
Phase:
Study type: Observational

The aim of the study is to assess the prevalence of peanut, tree nuts, and sesame allergy in Polish children at high risk of food allergy. Additionally, the timing of the development of peanut, tree nuts and sesame allergy in the first three years of life in a high-risk population will be assessed.

NCT ID: NCT05621317 Recruiting - Clinical trials for Immune System Diseases

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.

NCT ID: NCT05503446 Recruiting - Peanut Allergy Clinical Trials

Using Commonly Available Food Products To Treat Food Allergy

NATASHA
Start date: January 19, 2023
Phase: N/A
Study type: Interventional

Food allergy affects 1 in 30 children, and is the commonest trigger for life-threatening reactions (anaphylaxis) in this age group. It is a major public health issue, with practical implications for industry, education and healthcare systems. Oral immunotherapy (OIT) is an emerging treatment option, where small, increasing doses of a food allergen are used to cause "desensitisation", so food-allergic individuals no longer have symptoms when exposed to the trigger food. However, frequent allergic reactions during OIT (including anaphylaxis) are common, and can lead to patients having to stop treatment. In addition, food-allergic children usually dislike the taste of the food they are allergic too, which affects compliance and treatment success. There is a lack of longer-term data to inform cost-effectiveness analyses for OIT. The NATASHA study will recruit young people from age 6+ years with IgE-mediated peanut allergy, and young people aged 3+ years with IgE-mediated allergy to cow's milk, who will undergo oral immunotherapy for these allergens using real-world foods (taken carefully according to a standardised protocol under medical supervision). In addition to assessing efficacy and safety outcomes, we will also collect longer-term data to evaluate cost-effectiveness in the UK setting.

NCT ID: NCT05476497 Recruiting - Peanut Allergy Clinical Trials

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

PROTECT
Start date: October 17, 2022
Phase: Phase 1
Study type: Interventional

This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.

NCT ID: NCT05440643 Recruiting - Peanut Allergy Clinical Trials

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Start date: September 7, 2022
Phase: Phase 1
Study type: Interventional

This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet.